What is Journey Medical Corp's earnings per share (EPS)?

Journey Medical Corp (DERM) reported diluted earnings per share of $-0.47 for fiscal year 2025. This represents a 34.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Journey Medical Corp Financials

DERM

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Journey Medical Corp (DERM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DERM FY2025 2026-05-13

Journey Medical’s recent pattern is a paper margin recovery that still relies on working-capital funding instead of self-funded cash generation.

Between FY2024 and FY2025, the income statement improved even as operating cash flow worsened, creating an earnings-quality split across the same recovery period. The clearest bridge is accounts receivable, which jumped from $10.2M to $29.8M, so better reported results were offset by slower cash collection.

FY2025 still showed a high gross-margin model at 66.2%, and the operating loss was meaningfully smaller than in FY2024, which suggests the revenue base can support healthier economics when sales stabilize. But R&D spending fell to $480K from $9.9M, so part of the rebound came from lighter internal investment rather than from cash-generative scale.

The balance sheet looks liquid but externally supported, with a current ratio of 1.8x and cash of $24.1M, which gives more short-term flexibility than the loss line alone suggests. Yet financing cash flow added $16.2M while operations consumed cash, so the business still depended on outside capital to cover its operating needs.

Financial Health Signals

Financial Health Score 25/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Journey Medical Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

R&D Intensity

Revenue Progress

Balance Sheet

Altman Z-Score Distress

0.96

Journey Medical Corp scores 0.96, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($175.4M) relative to total liabilities ($62.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Journey Medical Corp passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

1.09x

For every $1 of reported earnings, Journey Medical Corp generates $1.09 in operating cash flow (-$12.4M OCF vs -$11.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-2.2x

Journey Medical Corp earns $-2.2 in operating income for every $1 of interest expense (-$8.2M vs $3.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$61.9M

YoY+10.2%

5Y CAGR+6.8%

Journey Medical Corp generated $61.9M in revenue in fiscal year 2025. This represents an increase of 10.2% from the prior year.

EBITDA

N/A

Net Income

-$11.4M

YoY+22.1%

Journey Medical Corp reported -$11.4M in net income in fiscal year 2025. This represents an increase of 22.1% from the prior year.

EPS (Diluted)

$-0.47

YoY+34.7%

Journey Medical Corp earned $-0.47 per diluted share (EPS) in fiscal year 2025. This represents an increase of 34.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$24.1M

YoY+18.6%

5Y CAGR+23.9%

Journey Medical Corp held $24.1M in cash against $25.3M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

66.2%

YoY+3.4pp

5Y CAGR-1.1pp

Journey Medical Corp's gross margin was 66.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.4 percentage points from the prior year.

Operating Margin

-13.2%

YoY+11.2pp

5Y CAGR-30.8pp

Journey Medical Corp's operating margin was -13.2% in fiscal year 2025, reflecting core business profitability. This is up 11.2 percentage points from the prior year.

Net Margin

-18.5%

YoY+7.7pp

5Y CAGR-30.3pp

Journey Medical Corp's net profit margin was -18.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.7 percentage points from the prior year.

Return on Equity

-35.9%

YoY+37.2pp

5Y CAGR-87.2pp

Journey Medical Corp's ROE was -35.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 37.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$480K

YoY-95.1%

Journey Medical Corp invested $480K in research and development in fiscal year 2025. This represents a decrease of 95.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

DERM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$61.9M+10.2%	$56.1M-29.1%	$79.2M+7.5%	$73.7M+16.7%	$63.1M+41.8%	$44.5M
Cost of Revenue	$20.9M+0.2%	$20.9M-8.8%	$22.9M-25.6%	$30.8M-4.1%	$32.1M+119.8%	$14.6M
Gross Profit	$40.9M+16.1%	$35.3M-37.4%	$56.3M+31.2%	$42.9M+38.1%	$31.1M+3.7%	$29.9M
R&D Expenses	$480K-95.1%	$9.9M+30.7%	$7.5M-31.1%	$10.9M+299.5%	$2.7M	N/A
SG&A Expenses	$44.4M+10.4%	$40.2M-8.4%	$43.9M-26.2%	$59.5M+49.3%	$39.8M+80.4%	$22.1M
Operating Income	-$8.2M+40.3%	-$13.7M-559.8%	-$2.1M+92.5%	-$27.5M+21.1%	-$34.9M-544.3%	$7.9M
Interest Expense	$3.7M+37.0%	$2.7M+59.0%	$1.7M-15.9%	$2.0M-71.3%	$7.0M+907.7%	$698K
Income Tax	$60K-1.6%	$61K-72.4%	$221K+250.8%	$63K-96.1%	$1.6M-12.6%	$1.9M
Net Income	-$11.4M+22.1%	-$14.7M-280.8%	-$3.9M+87.0%	-$29.6M+32.7%	-$44.0M-932.7%	$5.3M
EPS (Diluted)	$-0.47+34.7%	$-0.72-242.9%	$-0.21+87.6%	$-1.69+60.9%	$-4.32	$0.49

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$16.0M-0.7%	$16.1M-8.8%	$17.6M+17.5%	$15.0M+14.2%	$13.1M-3.5%	$13.6M-6.9%	$14.6M-1.5%	$14.9M
Cost of Revenue	$6.2M+14.3%	$5.4M-5.5%	$5.8M+16.5%	$4.9M+3.1%	$4.8M+114.1%	$2.2M-57.7%	$5.3M-19.2%	$6.5M
Gross Profit	$9.7M-8.4%	$10.6M-10.4%	$11.9M+17.9%	$10.1M+20.6%	$8.3M-26.7%	$11.4M+21.8%	$9.3M+12.4%	$8.3M
R&D Expenses	$39K	N/A	$287K	N/A	$39K-82.1%	$218K-74.1%	$842K-7.8%	$913K
SG&A Expenses	$10.1M+2.5%	$9.9M-18.2%	$12.1M+1.4%	$11.9M+12.4%	$10.6M+5.1%	$10.1M-11.7%	$11.4M+10.3%	$10.3M
Operating Income	-$1.5M-236.8%	-$443K+71.0%	-$1.5M+46.8%	-$2.9M+13.5%	-$3.3M-248.8%	$2.2M+177.2%	-$2.9M+1.1%	-$2.9M
Interest Expense	$892K-24.4%	$1.2M+45.0%	$814K+0.1%	$813K-8.8%	$891K-9.3%	$982K+46.3%	$671K+34.5%	$499K
Income Tax	N/A	N/A	N/A	$60K	N/A	N/A	N/A	N/A
Net Income	-$2.2M-78.8%	-$1.2M+46.1%	-$2.3M+39.0%	-$3.8M+6.8%	-$4.1M-367.8%	$1.5M+163.6%	-$2.4M+28.9%	-$3.4M
EPS (Diluted)	$-0.08	N/A	$-0.09+43.8%	$-0.16+11.1%	$-0.18	N/A	$-0.12+29.4%	$-0.17

DERM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$94.6M+17.9%	$80.2M+4.4%	$76.8M-26.9%	$105.2M+8.1%	$97.3M+87.4%	$51.9M
Current Assets	$66.9M+38.8%	$48.2M-14.7%	$56.5M-27.3%	$77.7M-8.1%	$84.5M+139.8%	$35.2M
Cash & Equivalents	$24.1M+18.6%	$20.3M-26.0%	$27.4M-14.3%	$32.0M-34.8%	$49.1M+495.2%	$8.2M
Inventory	$9.6M-33.3%	$14.4M+41.4%	$10.2M-27.9%	$14.2M+43.6%	$9.9M+602.4%	$1.4M
Accounts Receivable	$29.8M+191.1%	$10.2M-32.8%	$15.2M-46.0%	$28.2M+22.0%	$23.1M-3.4%	$23.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$62.7M+4.3%	$60.2M+6.5%	$56.5M-35.9%	$88.2M+59.6%	$55.2M+32.7%	$41.6M
Current Liabilities	$37.4M+6.4%	$35.2M-16.0%	$41.9M-37.4%	$66.8M+29.5%	$51.6M+83.9%	$28.1M
Long-Term Debt	$25.3M+1.6%	$24.9M+70.1%	$14.6M-26.2%	$19.8M	N/A	N/A
Total Equity	$31.9M+58.7%	$20.1M-1.4%	$20.4M+19.8%	$17.0M-59.6%	$42.0M+308.5%	$10.3M
Retained Earnings	-$98.5M-13.1%	-$87.0M-20.3%	-$72.4M-5.6%	-$68.5M-76.2%	-$38.9M-859.3%	$5.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$91.5M-3.2%	$94.6M+11.0%	$85.2M+5.0%	$81.2M-4.5%	$85.0M+5.9%	$80.2M+25.3%	$64.0M-1.8%	$65.2M
Current Assets	$65.0M-2.9%	$66.9M+18.6%	$56.4M+10.0%	$51.3M-5.0%	$54.0M+12.1%	$48.2M+4.4%	$46.2M-0.7%	$46.5M
Cash & Equivalents	$27.2M+13.0%	$24.1M-3.4%	$24.9M+22.9%	$20.3M-3.7%	$21.1M+3.8%	$20.3M-9.6%	$22.5M-6.1%	$23.9M
Inventory	$9.3M-3.4%	$9.6M-18.6%	$11.8M-8.0%	$12.9M+2.8%	$12.5M-13.4%	$14.4M+22.4%	$11.8M+21.7%	$9.7M
Accounts Receivable	$25.0M-16.1%	$29.8M+65.6%	$18.0M+15.0%	$15.6M-13.2%	$18.0M+76.2%	$10.2M-4.1%	$10.7M+2.0%	$10.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$60.7M-3.2%	$62.7M+5.8%	$59.3M-4.2%	$61.9M-2.4%	$63.4M+5.4%	$60.2M+13.3%	$53.1M-1.4%	$53.9M
Current Liabilities	$37.8M+1.0%	$37.4M-5.7%	$39.7M-1.9%	$40.5M+0.6%	$40.2M+14.3%	$35.2M+5.5%	$33.3M-2.4%	$34.1M
Long-Term Debt	$22.9M-9.5%	$25.3M+29.4%	$19.5M-8.6%	$21.4M-7.5%	$23.1M-7.1%	$24.9M+25.7%	$19.8M+0.2%	$19.7M
Total Equity	$30.8M-3.2%	$31.9M+23.0%	$25.9M+34.6%	$19.2M-10.7%	$21.5M+7.3%	$20.1M+83.7%	$10.9M-3.3%	$11.3M
Retained Earnings	-$100.7M-2.3%	-$98.5M-1.3%	-$97.2M-2.4%	-$94.9M-4.2%	-$91.1M-4.7%	-$87.0M+1.7%	-$88.5M-2.8%	-$86.2M

DERM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$12.4M-36.3%	-$9.1M-274.2%	$5.2M+138.7%	-$13.5M-520.5%	-$2.2M-142.5%	$5.1M
Capital Expenditures	N/A	$15.0M+200.0%	$5.0M-75.0%	$20.0M	N/A	N/A
Free Cash Flow	N/A	-$24.1M-10152.9%	$240K+100.7%	-$33.5M	N/A	N/A
Investing Cash Flow	N/A	-$15.0M-200.0%	-$5.0M+75.0%	-$20.0M-100.0%	-$10.0M-733.3%	-$1.2M
Financing Cash Flow	$16.2M-4.5%	$17.0M+453.7%	-$4.8M-129.2%	$16.5M-69.0%	$53.0M+10986.2%	-$487K
Dividends Paid	N/A	N/A	N/A	N/A	$820K	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$2.9M+146.3%	-$6.3M-163.7%	-$2.4M-153.0%	-$942K+66.7%	-$2.8M-227.3%	$2.2M+292.3%	-$1.2M+77.6%	-$5.2M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$220K-95.9%	$5.4M-22.9%	$7.0M+4165.5%	$165K-95.4%	$3.6M-66.1%	$10.6M+3711.9%	-$294K-105.8%	$5.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

DERM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	66.2%+3.4pp	62.8%-8.3pp	71.1%+12.9pp	58.2%+9.1pp	49.2%-18.1pp	67.2%
Operating Margin	-13.2%+11.2pp	-24.4%-21.7pp	-2.6%+34.7pp	-37.4%+17.9pp	-55.3%-72.9pp	17.6%
Net Margin	-18.5%+7.7pp	-26.1%-21.3pp	-4.9%+35.4pp	-40.2%+29.5pp	-69.7%-81.5pp	11.9%
Return on Equity	-35.9%+37.2pp	-73.1%-54.2pp	-18.9%+155.5pp	-174.5%-69.8pp	-104.6%-156.0pp	51.3%
Return on Assets	-12.1%+6.2pp	-18.3%-13.3pp	-5.0%+23.2pp	-28.2%+17.0pp	-45.2%-55.4pp	10.2%
Current Ratio	1.79+0.4	1.37+0.0	1.35+0.2	1.16-0.5	1.64+0.4	1.26
Debt-to-Equity	0.79-0.4	1.24+0.5	0.72-0.4	1.17-0.1	1.31-2.7	4.04
FCF Margin	N/A	-43.0%-43.3pp	0.3%+45.8pp	-45.5%	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	61.0%-5.1pp	66.2%-1.2pp	67.4%+0.3pp	67.1%+3.6pp	63.5%-20.0pp	83.6%+19.7pp	63.9%+7.9pp	56.0%
Operating Margin	-9.3%-6.6pp	-2.8%+5.9pp	-8.7%+10.5pp	-19.2%+6.1pp	-25.3%-41.7pp	16.4%+36.2pp	-19.8%-0.1pp	-19.7%
Net Margin	-14.0%-6.2pp	-7.8%+5.4pp	-13.1%+12.2pp	-25.3%+5.7pp	-31.0%-42.2pp	11.2%+27.5pp	-16.3%+6.3pp	-22.6%
Return on Equity	-7.2%-3.3pp	-3.9%+5.0pp	-8.9%+10.8pp	-19.7%-0.8pp	-18.9%-26.5pp	7.6%+29.4pp	-21.9%+7.9pp	-29.8%
Return on Assets	-2.4%-1.1pp	-1.3%+1.4pp	-2.7%+2.0pp	-4.7%+0.1pp	-4.8%-6.7pp	1.9%+5.6pp	-3.7%+1.4pp	-5.2%
Current Ratio	1.72-0.1	1.79+0.4	1.42+0.2	1.27-0.1	1.34-0.0	1.37-0.0	1.38+0.0	1.36
Debt-to-Equity	0.74-0.1	0.79+0.0	0.75-0.4	1.11+0.0	1.07-0.2	1.24-0.6	1.81+0.1	1.75
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

China Sxt Pharmaceuticals Inc SXTC

$2.7M

Ironwood IRWD

$643.6M

Organigram Global Inc OGI

$132.2M

BioAge Labs Inc. BIOA

$928.2M

Citius Oncology, Inc. CTOR

$51.7M

Frequently Asked Questions

What is Journey Medical Corp's annual revenue?

Journey Medical Corp (DERM) reported $61.9M in total revenue for fiscal year 2025. This represents a 10.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Journey Medical Corp's revenue growing?

Journey Medical Corp (DERM) revenue grew by 10.2% year-over-year, from $56.1M to $61.9M in fiscal year 2025.

Is Journey Medical Corp profitable?

No, Journey Medical Corp (DERM) reported a net income of -$11.4M in fiscal year 2025, with a net profit margin of -18.5%.

How much debt does Journey Medical Corp have?

As of fiscal year 2025, Journey Medical Corp (DERM) had $24.1M in cash and equivalents against $25.3M in long-term debt.

What is Journey Medical Corp's gross margin?

Journey Medical Corp (DERM) had a gross margin of 66.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Journey Medical Corp's operating margin?

Journey Medical Corp (DERM) had an operating margin of -13.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Journey Medical Corp's net profit margin?

Journey Medical Corp (DERM) had a net profit margin of -18.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Journey Medical Corp's return on equity (ROE)?

Journey Medical Corp (DERM) has a return on equity of -35.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Journey Medical Corp's operating cash flow?

Journey Medical Corp (DERM) generated -$12.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Journey Medical Corp's total assets?

Journey Medical Corp (DERM) had $94.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Journey Medical Corp spend on research and development?

Journey Medical Corp (DERM) invested $480K in research and development during fiscal year 2025.

What is Journey Medical Corp's current ratio?

Journey Medical Corp (DERM) had a current ratio of 1.79 as of fiscal year 2025, which is generally considered healthy.

What is Journey Medical Corp's debt-to-equity ratio?

Journey Medical Corp (DERM) had a debt-to-equity ratio of 0.79 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Journey Medical Corp's return on assets (ROA)?

Journey Medical Corp (DERM) had a return on assets of -12.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Journey Medical Corp's cash runway?

Based on fiscal year 2025 data, Journey Medical Corp (DERM) had $24.1M in cash against an annual operating cash burn of $12.4M. This gives an estimated cash runway of approximately 23 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Journey Medical Corp's Altman Z-Score?

Journey Medical Corp (DERM) has an Altman Z-Score of 0.96, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Journey Medical Corp's Piotroski F-Score?

Journey Medical Corp (DERM) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Journey Medical Corp's earnings high quality?

Journey Medical Corp (DERM) has an earnings quality ratio of 1.09x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Journey Medical Corp cover its interest payments?

Journey Medical Corp (DERM) has an interest coverage ratio of -2.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Journey Medical Corp?

Journey Medical Corp (DERM) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.